Literature DB >> 3095944

Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.

M Verstraete, C A Su, P Tanswell, W Feuerer, D Collen.   

Abstract

Pharmacokinetics and pharmacological effects of two intravenous doses of recombinant tissue-type plasminogen activator (rt-PA) (40 and 60 mg over 90 min) were determined in healthy volunteers. Mean maximum plasma concentrations were 1080 and 1560 ng/ml respectively. The steady state level during subsequent maintenance infusion of 30 mg over 6 h was 250 ng/ml. The pharmacokinetics of rt-PA showed a bi-exponential disappearance from plasma consistent with a 2-compartment model of t1/2 alpha = 5.7 min, a t1/2 beta = 1.3 h and a total clearance of 380 ml/min. Mean fibrinogen levels at the end of the infusions of 40 mg or 60 mg rt-PA over 90 min, measured in thawed plasma samples collected on citrate/aprotinin, decreased to 74% and 57% of the preinfusion values respectively. Plasminogen fell to 55% and 48%, and alpha 2-antiplasmin to 28% and 18% of initial values. No further decrease of these parameters was observed during the infusion of 30 mg rt-PA over 6 h. Only 2% of the preinfusion fibrinogen levels could be recovered as fibrinogen-fibrin degradation products. This moderate extent of systemic fibrinogenolysis is much less than that reported for therapeutic i.v. infusions of streptokinase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095944

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

Review 1.  Physiological balance of haemostasis and bleeding.

Authors:  V J Marder; C W Francis
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials: A report from the Working Group of International Congress of Interventional Neurology.

Authors:  Adnan I Qureshi; Foad Abd-Allah; Aitziber Aleu; John J Connors; Ricardo A Hanel; Ameer E Hassan; Haitham M Hussein; Nazli A Janjua; Rakesh Khatri; Jawad F Kirmani; Mikael Mazighi; Heinrich P Mattle; Jefferson T Miley; Thanh N Nguyen; Gustavo J Rodriguez; Qaisar A Shah; Adnan H Siddiqui; Jose I Suarez; M Fareed K Suri; Reha Tolun
Journal:  J Vasc Interv Neurol       Date:  2014-05

Review 3.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 4.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

Review 5.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10

Review 6.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 7.  Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children: A Review.

Authors:  Catherine Ross; Riten Kumar; Marie-Claude Pelland-Marcotte; Shivani Mehta; Monica E Kleinman; Ravi R Thiagarajan; Muhammad B Ghbeis; Christina J VanderPluym; Kevin G Friedman; Diego Porras; Francis Fynn-Thompson; Samuel Z Goldhaber; Leonardo R Brandão
Journal:  Chest       Date:  2021-09-26       Impact factor: 9.410

8.  Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys.

Authors:  Eriko Suzuki; Naoko Nishimura; Tetsuya Yoshikawa; Yudai Kunikiyo; Keiko Hasegawa; Keiji Hasumi
Journal:  Pharmacol Res Perspect       Date:  2018-12-05

Review 9.  Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke.

Authors:  Keiji Hasumi; Eriko Suzuki
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.